- IAN NISBET, PhD MAICD
Non Executive Chair
- Dr. Ian Nisbet is currently a partner at Afandin Pty Ltd., a life sciences consultancy company and Deputy Director (Commercialisation) at the Australian Institute for Bioengineering and Nanotechnology. Ian has more than 3 decades of pharmaceutical industry experience, including roles as CEO and managing Director of Xenome Ltd.; CEO of Meditech Research Ltd.; Senior Director, Business Development and Oncology Alliance Management at Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, and more than 17 years at CSL Ltd. Ian was Board Chair for Adipogen Pharmaceuticals Pty Ltd. He is currently the Board Chair for vivoPharm Pty Ltd. and sits on the Board of Velacor Pty Ltd.
- MICHAEL A. COWLEY, PhD FTSE
- Professor Michael A. Cowley Professor Michael Cowley returned to Australia in 2008 to establish and Direct the Monash Obesity and Diabetes Institute (MODI). Michael has over 15 years experience in research and biopharmaceutical drug development. Prior to founding MODI, he was the founder and Chief Scientific Officer of Orexigen Therapeutics, Inc., a publicly listed (NASDAQ: OREX) biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Michael’s previous positions include Core Director, and Associate Scientist at Oregon Health & Sciences University. Intellectual property that he developed led to the foundation of Thiakis Inc., and validated the obesity drug target serotonin 2C receptor, now under development by Arena Pharmaceuticals. Michael has published more than 60 papers and is the inventor of ~80 patents related to obesity, diabetes and the role of the CNS in metabolic disorders. In 2009, he was awarded the prestigious Commonwealth Science Minister’s Prize for Life Scientist of the Year and the Pfizer Australia Senior Research Fellowship. He was the recipient of a Victorian Endowment for Science, Knowledge, and Innovation (VESKI) Fellowship in 2008. He is a member of the Scientific Advisory Board of The Centre for Obesity Research and Education (CORE), The Alfred Hospital, Melbourne, Australia, and Gubra ApS, Denmark.
- PETER DEVINE, PhD MBA FAICD
- Dr. Peter Devine is currently the Chief Executive Officer for Uniseed, a $60 million pre-seed venture capital fund operating out of the Universities of Melbourne, New South Wales and Queensland. In this role, Peter is responsible for implementing Uniseed strategy and managing the company’s investment activities with a team of three Investment Managers. Peter has extensive experience at board and executive management levels in early stage technology start-up companies. He has held senior R&D, business development and commercialisation positions in a number of Australian companies, as well as Australian universities. Before joining Uniseed, Peter was Vice President of Business Development at Progen Industries Ltd. He was Research, Development and Commercialisation Manager at Brisbane-based PanBio Pty Ltd from 1996 to 2000 and also worked in Business Development at UniQuest Pty Ltd, the commercialisation arm of University of Queensland. He is a recipient of the Commonwealth of Australia Centenary Medal for ‘distinguished service to business in the biotechnology industry’.
- STEVE GOURLAY, MBBS PhD MBA
Non Executive Director
- Dr Steve Gourlay is a partner at GBS Venture Partners. Steve joined GBS in 2005 and has more than 20 years experience in drug and medical device development. Steve previously had a number of senior roles in development at Genentech Inc. in California. He also taught epidemiology, clinical research methods and clinical pharmacology at the University of California, San Francisco. Steve is on the board of directors of NeuroVista Inc, AiMedics Pty Ltd, Applied Physiology Ptd Ltd, Endoluminal Science Pty Ltd and Elastagen Ptd Ltd. Steve is a licensed consultant physician in Internal Medicine. He received his PhD from Monash University after completing a series of observational and interventional studies of novel smoking cessation medications. He subsequently undertook a postdoc in clinical pharmacology at UCSF and a MBA at Macquarie University. He has published more than 30 peer-reviewed reports of clinical research.
- KATHERINE NIELSEN, PhD M.Intell. Prop. Law M.Pharm. GAICD
Non Executive Director
- Dr. Kathy Nielsen is the Senior Investment Manager at QIC Bioventures, a boutique investment fund of QIC. Kathy has 25 years experience in the life science field ranging from pharmaceutical research (Victorian College of Pharmacy, University of Toronto) and industry (Sigma Pharmaceuticals) to technology transfer, commercialisation and finance - developing early stage technologies with a focus on new therapeutics and medical devices. Kathy received her PhD from Monash University (Victorian College of Pharmacy) in medicinal chemistry, followed by a post-doctoral position at the University of Queensland. She has authored more than 25 peer reviewed publications and is inventor on several patents. Her recent previous roles include Executive Officer (ElaCor Pty Ltd), Director of Intellectual Property (Xenome Ltd) and Manager, Intellectual Property and Development (IMBcom Pty Ltd). Previous Board positions include Protagonist Inc, ElaCor Pty Ltd, Cellixe Pty Ltd and Nanomics BioSystems Pty Ltd. Currently Kathy is investment manager for several US and Australian companies and holds a number of additional board positions as Director (Relevare Pharmaceuticals Inc., Shape Pharmaceuticals Pty Ltd) or Observer (Advent Pharmaceuticals Pty Ltd, Hatchtech Pty Ltd, Gelesis Inc.). Kathy is a 2010 recipient of a Queensland Smart State Commercialisation Fellowship (Investment Innovation Exchange)..